Who is sponsoring NCT00636935?

NCT00636935 is sponsored by George Washington University.

What drugs are being tested in NCT00636935?

Interventions in NCT00636935: Antibiotics only, Antibiotics + Corticosteroids, Corticosteroids + antibiotics.

What condition does NCT00636935 study?

NCT00636935 studies Pneumocystis Carinii Pneumonia.

Is NCT00636935 still recruiting?

NCT00636935 is currently withdrawn. Last updated 23 June 2017.

Last reviewed 2017-06-23 · How we verify

NCT00636935

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Oral Corticosteroids Therapy and Interstitial Fibrosis in Patients With Pneumocystis Jirovecii Pneumonia (PCP) and pO2 of >70 at Presentation.

Withdrawn Phase 4 Last updated 23 June 2017

What this trial tests

Phase 4 trial testing Antibiotics only in Pneumocystis Carinii Pneumonia. Withdrawn.

Timeline

1 February 2008

Primary endpoint
1 August 2013

1 August 2013

Quick facts

Lead sponsor	George Washington University
Phase	Phase 4
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Start date	1 February 2008
Primary completion	1 August 2013
Estimated completion	1 August 2013
Sites	1 location across United States

Drugs / interventions tested

Antibiotics only — full drug profile →
Antibiotics + Corticosteroids — full drug profile →
Corticosteroids + antibiotics — full drug profile →

Conditions studied

Pneumocystis Carinii Pneumonia — all drugs for Pneumocystis Carinii Pneumonia →

Sponsor

George Washington University

Who can join

18 and older, any sex, with Pneumocystis Carinii Pneumonia. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Changes in pulmonary function testing and DLCO measurements in patients with PCP and pO2 > 70 mmHg.
Time frame: 1 month, 3 months and 6 months after diagnosis
Changes in pulmonary function testing and DLCO measurements in patients with PCP and pO2 \> 70 mmHg.

Sponsor's own description

To explore the effects of corticosteroid therapy on pulmonary fibrosis and potentially pneumothorax in patients with mild PCP (pO2 \>70mmHg) combined with the standard of care treatment of antibiotic therapy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other George Washington University trials

Trials by the same sponsor.

NCT07279129 — Decision Support Tool to Integrate PrEP Into Emergency Departments · Phase 1 · not yet recruiting
NCT07524309 — Self-Help Plus Pilot Study, Colombia: Train2Care · NA · not yet recruiting
NCT07249008 — NSS Grocery Store Brazil · NA · recruiting
NCT07000513 — HIV Self-Testing and Long-Acting Injectables for HIV Treatment and Prevention Among Commercial Minibus Drivers (I-TEST L · Phase 4 · not yet recruiting
NCT07079306 — ChatGPT-Supported Text Messaging Program for Smoking Cessation · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00636935 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by George Washington University
Last refreshed: 23 June 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00636935.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing